JIANGSU GDK(SH:688670)2023-04-19 16:00Financial Performance - The company's revenue for Q1 2023 reached ¥106,219,935.77, representing a significant increase of 751.94% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥36,346,153.06, with a substantial growth attributed to increased sales during the quarter[5][8]. - The basic and diluted earnings per share for the quarter were both ¥0.41, reflecting the company's strong performance[6]. - In Q1 2023, the company reported a net profit of CNY 36,346,153.06, a significant recovery from a net loss of CNY 2,641,751.10 in Q1 2022, marking a turnaround of over 1,400%[19]. - Operating profit for Q1 2023 was CNY 41,239,941.04, compared to an operating loss of CNY 281,074.90 in the same period last year[19]. - The company’s total profit for Q1 2023 was CNY 40,748,976.62, compared to a loss of CNY 270,416.31 in the same quarter last year[19]. Revenue and Costs - Total operating revenue for Q1 2023 reached RMB 106,219,935.77, a significant increase from RMB 12,468,040.78 in Q1 2022, representing a growth of approximately 752.5%[18]. - Total operating costs for Q1 2023 were RMB 74,836,834.78, compared to RMB 21,145,299.52 in Q1 2022, indicating an increase of about 353.5%[18]. - Total revenue from sales of goods and services reached CNY 94,157,637.00, up from CNY 80,436,361.90 in Q1 2022, representing an increase of approximately 17.5%[22]. Cash Flow and Assets - The net cash flow from operating activities was ¥6,437,234.74, showing a growth of 4.94% compared to the previous year[5]. - The company's cash and cash equivalents as of March 31, 2023, amounted to RMB 265,761,691.20, up from RMB 174,728,926.82 at the end of 2022, reflecting a growth of approximately 52.0%[14]. - Cash and cash equivalents at the end of Q1 2023 totaled CNY 265,761,691.20, a substantial increase from CNY 116,257,683.14 at the end of Q1 2022, reflecting a growth of over 128%[23]. - The company generated a net cash flow from operating activities of CNY 6,437,234.74, slightly up from CNY 6,134,019.46 in Q1 2022[22]. - Investment activities generated a net cash inflow of CNY 78,018,421.33, compared to CNY 63,593,297.03 in Q1 2022, indicating a growth of approximately 22.6%[23]. Shareholder Information - The company reported a total of 4,729 common shareholders at the end of the reporting period[10]. - The top two shareholders, Yu Jun and Zhang Liangbin, each hold 30.74% of the shares, totaling 27,049,291 shares[10]. Research and Development - Research and development expenses totaled ¥6,559,451.54, accounting for 6.18% of revenue, a decrease of 38.92 percentage points year-on-year[6]. - The company reported an increase in research and development expenses to CNY 3,100,291.99 from CNY 2,949,671.40 in the previous year, reflecting a commitment to innovation[19]. Assets and Liabilities - Total assets at the end of the quarter were ¥1,877,139,584.80, an increase of 2.76% from the end of the previous year[6]. - Total assets as of March 31, 2023, were RMB 1,877,139,584.80, compared to RMB 1,826,776,950.09 at the end of 2022, marking an increase of approximately 2.8%[16]. - Total liabilities as of March 31, 2023, amounted to RMB 381,121,533.52, up from RMB 367,105,051.87 at the end of 2022, indicating a growth of about 3.0%[16]. - The company's non-current assets totaled RMB 881,896,549.21 as of March 31, 2023, slightly increasing from RMB 875,761,410.71 at the end of 2022, reflecting a growth of approximately 0.1%[15]. Market Demand - The company experienced a surge in demand for flu vaccines due to a high incidence of flu in multiple regions, contributing to the sales growth[8]. Other Information - The company has not disclosed any new product launches or technological advancements during this reporting period[12]. - There are no significant mergers or acquisitions reported in the current quarter[12]. - The company's financial expenses decreased significantly, with interest expenses reported at CNY 428,300.02, compared to CNY 166,249.99 in Q1 2022[19].